# X4 Pharmaceuticals, Inc: overview XFOR · Nasdaq · CIK 1501697 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xfor.md) · [Financials](/companies/xfor/financials.md) · [Filings](/companies/xfor/filings.md) · [Insiders](/companies/xfor/insiders.md) Latest reported revenue: [$8.8m](/filings/0001501697-26-000068.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001501697-26-000068). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.6](/filings/0001501697-25-000043.md) | [1.4 d](/filings/0001501697-26-000018.md) | [28.8](/filings/0001501697-26-000040.md) | [2.0](/filings/0001501697-26-000068.md) | [1.8](/filings/0001501697-25-000043.md) | [2.6 d](/filings/0001501697-26-000018.md) | [2.7](/filings/0001501697-26-000040.md) | [8.8](/filings/0001501697-26-000068.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(6160.7%)](/filings/0001501697-25-000043.md) | [(2490.6%) d](/filings/0001501697-26-000018.md) | [(32.8%)](/filings/0001501697-26-000040.md) | [(1329.5%)](/filings/0001501697-26-000068.md) | [(1558.6%)](/filings/0001501697-25-000043.md) | [(922.9%) d](/filings/0001501697-26-000018.md) | [(749.9%)](/filings/0001501697-26-000040.md) | [(186.1%)](/filings/0001501697-26-000068.md) | | Net margin | % | [(6552.9%)](/filings/0001501697-25-000043.md) | [(2776.9%) d](/filings/0001501697-26-000018.md) | [1.0%](/filings/0001501697-26-000068.md) | [(1304.7%)](/filings/0001501697-26-000068.md) | [(1689.2%)](/filings/0001501697-25-000043.md) | [(931.7%) d](/filings/0001501697-26-000018.md) | [(747.5%)](/filings/0001501697-26-000068.md) | [(183.5%)](/filings/0001501697-26-000068.md) | | Diluted EPS | $ per share | [(5.48)](/filings/0001501697-25-000043.md) | not reported | [0.04](/filings/0001501697-26-000040.md) | [(3.47)](/filings/0001501697-26-000068.md) | [(0.69)](/filings/0001501697-25-000043.md) | not reported | [(0.16)](/filings/0001501697-26-000040.md) | [(0.13)](/filings/0001501697-26-000068.md) | | Free cash flow | $m | [(34.1) d](/filings/0001501697-25-000043.md) | [(33.0) d](/filings/0001501697-26-000018.md) | [(12.4)](/filings/0001501697-26-000040.md) | [(29.9) d](/filings/0001501697-26-000068.md) | [(27.8) d](/filings/0001501697-25-000043.md) | [(15.5) d](/filings/0001501697-26-000018.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001628280-23-008745.md) | [0.0](/filings/0001628280-25-014805.md) | [0.0](/filings/0001501697-26-000018.md) | [2.6](/filings/0001501697-26-000018.md) | [35.1](/filings/0001501697-26-000018.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(1423.6%)](/filings/0001501697-26-000018.md) | [(247.4%)](/filings/0001501697-26-000018.md) | | Net margin | % | not reported | not reported | not reported | [(1464.6%)](/filings/0001501697-26-000018.md) | [(225.6%)](/filings/0001501697-26-000018.md) | | Diluted EPS | $ per share | [(3.99)](/filings/0001628280-24-012578.md) | [(1.52)](/filings/0001628280-25-014805.md) | [(17.07)](/filings/0001501697-26-000018.md) | [(5.59)](/filings/0001501697-26-000018.md) | [(1.87)](/filings/0001501697-26-000018.md) | | Free cash flow | $m | [(71.5)](/filings/0001628280-24-012578.md) | [(77.2)](/filings/0001628280-25-014805.md) | [(96.6)](/filings/0001501697-26-000018.md) | [(131)](/filings/0001501697-26-000018.md) | [(85.6)](/filings/0001501697-26-000018.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xfor/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $44.2m | 9,461,279 | | Reduced −5,713 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $38.9m | 8,321,657 | | Added +218,257 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $37.2m | 7,967,454 | | Unchanged | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $37.0m | 7,933,491 | | Added +1,195,843 | | [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $32.6m | 6,973,343 | | Added +516,697 | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $32.4m | 6,930,591 | | Reduced −2,013,527 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $27.5m | 5,878,757 | | Reduced −460,778 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $25.9m | 5,554,906 | | Added +4,343,112 | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $17.4m | 3,722,840 | | Unchanged | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $17.4m | 3,722,840 | | Unchanged | ## Recent filings [All 810 filings](/companies/xfor/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 17:23 ET | [8-K](/filings/0001501697-26-000081.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001501697-26-000081 | | 2026-09-09 | 17:36 ET | [8-K](/filings/0001501697-26-000076.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001501697-26-000076 | | 2026-09-08 | 07:15 ET | [8-K](/filings/0001501697-26-000072.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001501697-26-000072 | | 2026-08-06 | 16:08 ET | [10-Q](/filings/0001501697-26-000068.md) | Quarterly report, period 2026-06-30 | 0001501697-26-000068 | | 2026-07-01 | 16:13 ET | [8-K](/filings/0001501697-26-000060.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001501697-26-000060 | | 2026-05-13 | 16:57 ET | [8-K/A](/filings/0001501697-26-000051.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001501697-26-000051 | | 2026-05-12 | 16:21 ET | [8-K](/filings/0001501697-26-000047.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001501697-26-000047 | | 2026-05-06 | 07:01 ET | [10-Q](/filings/0001501697-26-000040.md) | Quarterly report, period 2026-03-31 | 0001501697-26-000040 | | 2026-03-20 | 08:45 ET | [DEF 14A](/filings/0001501697-26-000031.md) | Proxy statement, period 2026-03-20 | 0001501697-26-000031 | | 2026-03-17 | 06:59 ET | [10-K](/filings/0001501697-26-000018.md) | Annual report, period 2025-12-31 | 0001501697-26-000018 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001501697-26-000018.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5572c82b-f663-469b-bcce-e2ba662476ae) ## About the filer - CIK: 1501697 - Tickers: XFOR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 10:01 ET. No prices; not investment advice.